{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TT+Vaccine",
    "query": {
      "intervention": "TT Vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TT+Vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T19:19:53.422Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00128219",
      "title": "Prevention of GBS Colonization Via Immunity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta Haemolytic Streptococcal Infection"
      ],
      "interventions": [
        {
          "name": "GBS III-TT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus and diptheria toxoids vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 667,
      "start_date": "2003-07",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 3,
      "location_summary": "Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128219"
    },
    {
      "nct_id": "NCT03063736",
      "title": "Entolimod, an Adjuvant for Vaccine Augmentation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Entolimod",
          "type": "DRUG"
        },
        {
          "name": "Td Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2017-12-08",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03063736"
    },
    {
      "nct_id": "NCT03848182",
      "title": "Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "TT vaccine booster",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-07-21",
      "completion_date": "2019-11-11",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03848182"
    },
    {
      "nct_id": "NCT02960230",
      "title": "H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant"
      ],
      "interventions": [
        {
          "name": "K27M peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sabine Mueller, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 50,
      "start_date": "2016-11-18",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-22",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 14,
      "location_summary": "San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960230"
    },
    {
      "nct_id": "NCT00129129",
      "title": "Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Haemophilus Influenzae Type b",
        "Neisseria Meningitidis"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ActHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Menomune",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "6 Weeks to 15 Months"
      },
      "enrollment_count": 756,
      "start_date": "2004-08-01",
      "completion_date": "2006-03-29",
      "has_results": true,
      "last_update_posted_date": "2018-08-24",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 27,
      "location_summary": "Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129129"
    },
    {
      "nct_id": "NCT03650114",
      "title": "Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus toxoid (TT) containing vaccine (Td, Tdap)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13-valent pneumococcal conjugate vaccine (13-PCV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "23-valent pneumococcal polysaccharide vaccine (23-PPV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Seasonal Quadrivalent influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Keyhole limpet hemocyanin (KLH) neo-antigen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1882,
      "start_date": "2018-12-28",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03650114"
    },
    {
      "nct_id": "NCT00000105",
      "title": "Vaccination With Tetanus and KLH to Assess Immune Responses.",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Intracel KLH Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biosyn KLH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA51",
          "type": "DRUG"
        },
        {
          "name": "Tetanus toxoid",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2002-07",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000105"
    },
    {
      "nct_id": "NCT00345683",
      "title": "Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Haemophilus Influenzae Type b",
        "Neisseria Meningitidis"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PedvaxHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 4021,
      "start_date": "2007-07",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2016-11-29",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345683"
    },
    {
      "nct_id": "NCT00715910",
      "title": "The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Nimenrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Blood sampling",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "15 Years to 30 Years"
      },
      "enrollment_count": 818,
      "start_date": "2008-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-27",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 10,
      "location_summary": "Daly City, California • Fairfield, California • Redwood City, California + 6 more",
      "locations": [
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715910"
    },
    {
      "nct_id": "NCT00795457",
      "title": "Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Astrocytoma",
        "Oligo-Astrocytoma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "GAA/TT-peptide vaccine and poly-ICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ian F. Pollack, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2009-01",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2019-08-30",
      "last_synced_at": "2026-09-03T19:19:53.422Z",
      "location_count": 2,
      "location_summary": "Winston-Salem, North Carolina • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795457"
    }
  ]
}